SCHEMBL3550452

SCHEMBL3550452

Cc1ccc(-c2ccc3c(C)c(C(=O)c4ccc(Cl)cc4Cl)oc3c2)cc1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 2/20 0.52
MAPT P10636 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
HPGD P15428 2/20 0.38
LMNA P02545 1/20 0.38
HTT P42858 1/20 0.38
KCNH2 Q12809 1/20 0.38
RAB9A P51151 3/20 0.37
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
KMT2A Q03164 2/20 0.37
ALDH1A1 P00352 2/20 0.37
POLB P06746 1/20 0.37
CYP2C9 P11712 1/20 0.37
SRD5A2 P31213 1/20 0.36
HSD17B10 Q99714 1/20 0.36
KDM4E B2RXH2 1/20 0.36
THRB P10828 2/20 0.36
PPARG P37231 1/20 0.36
NCOA2 Q15596 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560389 0.88 MCL1 (0.52) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3102308 0.86 MCL1 (0.50) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3105311 0.84 MCL1 (0.48) MCL1MAPTSMN1; SMN2HPGDRAB9A
SCHEMBL3092548 0.84 MCL1 (0.48) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3554192 0.84 MCL1 (0.50) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3556744 0.84 MCL1 (0.47) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3108280 0.84 MCL1 (0.53) MCL1SMN1; SMN2RAB9AMEN1NPC1
SCHEMBL3099923 0.83 MCL1 (0.46) MCL1MAPTSMN1; SMN2HPGDLMNA
SCHEMBL3554326 0.83 KDM4E (0.47) MCL1MAPTSMN1; SMN2HPGDRAB9A
SCHEMBL3098263 0.83 MCL1 (0.46) MCL1MAPTSMN1; SMN2HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7659412-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER HEALTHCARE LLC (US) 2010-02-09 US disclosed
US-20090023783-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS ZHANG CHENGZHI 2009-01-22 US disclosed
US-7420066-B2 Benzofuran derivatives useful for treating hyper-proliferative disorders BAYER PHARMACEUTICALS CORPORATION (US) 2008-09-02 US disclosed
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders BAER PHAMACEUTICALS CORPORATION (US) 2006-08-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194816-A1 Benzofuran derivatives useful for treating hyper-proliferative disorders MKI67, PCNA, CCNI MCL1 55/4885MAPT 4163/4885SMN1; SMN2 3666/4885
US-20090023783-A1 BENZOFURAN DERIVATIVES USEFUL FOR TREATING HYPER-PROLIFERATIVE DISORDERS PCNA, MKI67, CDK4 MCL1 57/4885MAPT 4197/4885SMN1; SMN2 3770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.